Analysts are looking to Abbott Laboratories (ABT) this earnings season, with projected gains in Diagnostics and Medical Devices intersecting with new product launches and FDA-backed upgrades that could influence how investors frame the story. Recent product launches and the CardioMEMS app update have put Abbott Laboratories back in focus for many investors. The share price is still down 15.54% year to date, while the 3-year total shareholder return is up 15.44%. This suggests that longer term...

Analysts are looking to Abbott Laboratories (ABT) this earnings season, with projected gains in Diagnostics and Medical Devices intersecting with new product launches and FDA-backed upgrades that could influence how investors frame the story. Recent product launches and the CardioMEMS app update have put Abbott Laboratories back in focus for many investors. The share price is still down 15.54% year to date, while the 3-year total shareholder return is up 15.44%. This suggests that longer term...

Abbott Laboratories stock last stood at EUR 93.01 before weekend trading on October 16, 2026. The ne

A Georgia woman’s spinal cord stimulator lawsuit alleges she suffered painful shocks and permanent injuries after an Abbott device's leads migrated out of position.

Rothschild Redburn set a USD 127.00 target on October 2. Abbott Laboratories stock costs EUR 92.35 o

La demanda de un hombre de California alega que una válvula cardíaca Abbott Trifecta GT falló sólo ocho años después de su implantación, mucho antes de su vida útil anunciada de aproximadamente 15 a 20 años.

Both are Dividend Kings with decades of consecutive raises, but Medtronic and Abbott reward income investors in fundamentally different ways, and choosing the wrong one in retirement could cost you more than you expect.

Second-quarter revenue reached USD 12.59 billion, up 13.00 percent. Abbott Laboratories stock trades

Abbott Laboratories is expected to report third-quarter results on October 21. The stock was at EUR

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.